<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180101.dtd">
<PubmedArticleSet>

<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">29501528</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-7064</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Mar</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neuropharmacology</Title>
                <ISOAbbreviation>Neuropharmacology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S0028-3908(18)30099-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropharm.2018.02.033</ELocationID>
            <Abstract>
                <AbstractText>2,5-Dimethoxyphenethylamines (2C compounds) are 5-HT<sub>2A/2C</sub>receptor agonists that induce hallucinogenic effects. N-methoxybenzylation of 2C compounds markedly increases their affinity for 5-HT<sub>2A</sub>receptors, and two such analogs, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe), have emerged in recreational drug markets. Here, we investigated the neuropharmacology of 25C-NBOMe and 25I-NBOMe in rats, as compared to their 2C analogs and the prototypical 5-HT<sub>2A/2C</sub>agonist 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine (DOI). Compounds were tested in vitro using 5-HT<sub>2A</sub>receptor binding and calcium mobilization assays. For in vivo experiments, 25C-NBOMe (0.01-0.3 mg/kg), 25I-NBOMe (0.01-0.3 mg/kg), 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) (0.1-3.0 mg/kg), 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) (0.1-3.0 mg/kg) and DOI (0.03-1.0 mg/kg) were administered subcutaneously (sc) to male rats, and 5-HT<sub>2A</sub>-mediated behaviors were assessed. NBOMes displayed higher affinity for 5-HT<sub>2A</sub>receptors than their 2C counterparts but were substantially weaker in functional assays. 25C-NBOMe and 25I-NBOMe were much more potent at inducing wet dog shakes (WDS) and back muscle contractions (BMC) when compared to 2C-C and 2C-I. Pretreatment with the selective 5-HT<sub>2A</sub>antagonist (R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl}methanol (M100907) reversed behaviors produced by all agonists. Interestingly, binding affinities at the 5-HT<sub>2A</sub>receptor were significantly correlated with potencies to induce BMC but not WDS. Our findings show that NBOMes are highly potent 5-HT<sub>2A</sub>agonists in rats, similar to effects in mice, and consistent with the reported hallucinogenic effects in human users.</AbstractText>
                <CopyrightInformation>Copyright © 2018. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Elmore</LastName>
                    <ForeName>Joshua S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Decker</LastName>
                    <ForeName>Ann M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, 27709, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sulima</LastName>
                    <ForeName>Agnieszka</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Drug Design and Synthesis Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rice</LastName>
                    <ForeName>Kenner C</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Drug Design and Synthesis Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 20892, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Partilla</LastName>
                    <ForeName>John S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blough</LastName>
                    <ForeName>Bruce E</ForeName>
                    <Initials>BE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, 27709, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baumann</LastName>
                    <ForeName>Michael H</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA. Electronic address: mbaumann@mail.nih.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Neuropharmacology</MedlineTA>
            <NlmUniqueID>0236217</NlmUniqueID>
            <ISSNLinking>0028-3908</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-HT(2A) receptor</Keyword>
            <Keyword MajorTopicYN="N">Back muscle contractions</Keyword>
            <Keyword MajorTopicYN="N">NBOMe</Keyword>
            <Keyword MajorTopicYN="N">Wet dog shakes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29501528</ArticleId>
            <ArticleId IdType="pii">S0028-3908(18)30099-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2018.02.033</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
